医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Establishment of Mitsui Chemicals Thailand

2017年04月03日 PM02:00
このエントリーをはてなブックマークに追加


 

TOKYO

Mitsui Chemicals, Inc. (Tokyo: 4183; President & CEO: Tsutomu Tannowa) announced that it established Mitsui Chemicals (Thailand) Co., Ltd. in Bangkok, Thailand on April 3, 2017. With Mitsui Chemicals (Thailand) Co., Ltd. functioning as the Mitsui Chemicals Group distributor in Thailand, Mitsui Chemicals will bolster its marketing power and expand its business.

 

Outline of Mitsui Chemicals (Thailand) Co., Ltd.

Company name   Mitsui Chemicals (Thailand) Co., Ltd.
Establishment April 3, 2017
Capital

150 million bahts (Mitsui Chemicals 100%)

Location Bangkok
President Toshihiro Motoshima
Product Sales and Marketing of Mitsui Chemicals products
Commercial Operation   July 2017
 

Background of the establishment

An important market in Southeast Asia in the auto and packaging materials industries, Thailand is particularly vital for Mitsui Chemicals’ core Mobility and Food & Packaging businesses. Thailand has a concentration of major global companies in the field of health care, particularly spectacle lens materials. Mitsui Chemicals can thus expand in Thailand its Health Care business, another core business.
Before the establishment of Mitsui Chemicals Thailand, Mitsui Chemicals had six manufacturing and sales bases in Thailand. With this distributor in the important Thai market, Mitsui Chemicals will strengthen its operations in Thailand through local-based marketing and will expand sales in neighboring countries.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170402005021/en/

CONTACT

Mitsui Chemicals, Inc.
Takashi Kawamoto, +81-3-6253-2100
Corporate
Communications Division

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 20/20’s Lung Cancer Detection Technology Launches in China
  • PAREXEL and Osaka International Cancer Institute Form Alliance to Advance Clinical Research in Japan
  • PREVENA™ Incision Management System Shown to Reduce Incisional Pain and Associated Narcotic Use Among Obese Study Patients Undergoing Cesarean Delivery
  • Samsung Bioepis and Takeda Sign Strategic Collaboration Agreement to Co-Develop Multiple Novel Biologic Therapies
  • Ligand to Receive $2 Million from WuXi Biologics for Licensing Clinical-Stage anti-PD-1 Antibody Discovered Using the OmniAb® Technology